Publikationen, an denen er mitarbeitet Juan Antonio Pineda Vergara (38)

2022

  1. No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals

    PNAS Nexus, Vol. 1, Núm. 3

2021

  1. Cd46 genetic variability and hiv-1 infection susceptibility

    Cells, Vol. 10, Núm. 11

2019

  1. Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability

    Infection, Genetics and Evolution, Vol. 73, pp. 276-286

2015

  1. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection

    Genes and Immunity, Vol. 16, Núm. 2, pp. 134-141

  2. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

    AIDS

  3. Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  3. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection

    Molecular Biology and Evolution, Vol. 31, Núm. 9, pp. 2402-2414

  4. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection

    Journal of Infectious Diseases, Vol. 207, Núm. 3, pp. 411-419

  3. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  4. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  5. Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection

    AIDS, Vol. 27, Núm. 11, pp. 1697-1706

  6. Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

    PLoS ONE, Vol. 8, Núm. 4

  7. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  8. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

  9. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection

    Journal of Immunology, Vol. 188, Núm. 2, pp. 818-823